A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
Pfizer
Pfizer
Daehwa Pharmaceutical Co., Ltd.
Orano Med LLC
Bayer
Shengjing Hospital
Sunnybrook Health Sciences Centre
The Methodist Hospital Research Institute
Turku University Hospital
Institut Jean-Godinot
Pfizer
OncoTherapy Science, Inc.
Pfizer
CSPC Megalith Biopharmaceutical Co.,Ltd.
General Oncology, Inc.
DualityBio Inc.
OncoNano Medicine, Inc.
M.D. Anderson Cancer Center
UNC Lineberger Comprehensive Cancer Center
Cancer Trials Ireland
Ono Pharmaceutical Co. Ltd
Lyell Immunopharma, Inc.
Lyell Immunopharma, Inc.
University College, London
Esperas Pharma Inc.
MacroGenics
Stanford University
Dana-Farber Cancer Institute
Mundipharma Research Limited
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
National Cancer Institute (NCI)
Peter MacCallum Cancer Centre, Australia
European Organisation for Research and Treatment of Cancer - EORTC
Daehwa Pharmaceutical Co., Ltd.
Leap Therapeutics, Inc.
National Institutes of Health Clinical Center (CC)
KK Women's and Children's Hospital
Pfizer
Gangnam Severance Hospital
Severance Hospital
Nektar Therapeutics
University of Wisconsin, Madison
Protean BioDiagnostics
Kiadis Pharma
GBG Forschungs GmbH
British Columbia Cancer Agency
MedSIR
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Zhejiang Cancer Hospital
NKGen Biotech, Inc.
Dana-Farber Cancer Institute